Cytokinetics, Incorporated CYTK
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -0.87%
- 1 year
- +1.19%
- Open
- 63.44
- Prev close
- 63.31
- Mkt cap
- 8.76B
- Vol
- 1.26M
- Avg vol
- 1.92M
- EPS
- -7.22
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 62.55
- High
- 64.50
- Forward P/E
- -14.30
- Beta
- 0.41
- Short ratio
- 8.18
- Inst. own
- 126.00%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 67.78
- 200-d avg
- 70.09
- 1y target
- 107.26
5D chart
Signals (116)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 29, 3:25 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:05 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:00 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:55 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:40 PM | 3 days ago |
| RSI: Oversold | Oct 29, 2:20 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:50 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 12:40 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 12:20 PM | 3 days ago |
| RSI: Overbought | Oct 29, 12:15 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:00 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:40 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:10 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:45 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:40 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:25 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:15 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:25 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:10 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:45 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:30 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:05 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 12:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 11:50 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:50 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:25 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:10 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:45 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:25 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:35 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 9:35 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| RSI: Overbought | Oct 27, 3:55 PM | 5 days ago |
| RSI: Overbought | Oct 27, 3:35 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:35 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:25 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:20 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:20 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:10 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 1:40 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:35 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:35 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:25 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 1:25 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:55 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 12:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:50 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 12:50 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 12:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:35 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 12:35 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:30 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 12:30 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:25 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:20 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:20 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 12:20 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:15 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 11:50 AM | 5 days ago |
| SMA: Bullish | Oct 27, 11:40 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:10 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:10 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:00 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:00 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:00 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:55 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:55 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:35 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 5 days ago |
| SMA: Bullish | Oct 26, 3:55 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:45 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 3:30 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:25 PM | 6 days ago |
| RSI: Oversold | Oct 26, 3:00 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 2:40 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:35 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:20 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 2:20 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:15 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:10 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:05 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 1:30 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:25 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:25 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:10 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:55 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:50 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:30 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:30 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:20 PM | 6 days ago |
| SMA: Bullish | Oct 26, 11:55 AM | 6 days ago |
| SMA: Bearish | Oct 26, 11:45 AM | 6 days ago |
| SMA: Bullish | Oct 26, 11:40 AM | 6 days ago |
| SMA: Bearish | Oct 26, 11:20 AM | 6 days ago |
| SMA: Bullish | Oct 26, 11:10 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:25 AM | 6 days ago |
News
4 days ago zacks.com
Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Should You Buy?
Cytokinetics (CYTK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
6 days ago seekingalpha.com
Baron Health Care Fund Q3 2026 Top Contributors And Detractors
TMO's organic growth of 5% exceeded consensus by 200 basis points, and management raised full-year organic growth guidance/. MTD's local-currency sales grew 6%, exceeding prior guidance of 3%. TEVA…
1 week ago defenseworld.net
Contrasting Actinium Pharmaceuticals (NYSE:ATNM) and Cytokinetics (NASDAQ:CYTK)
Actinium Pharmaceuticals (NYSE: ATNM - Get Free Report) and Cytokinetics (NASDAQ: CYTK - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two…
1 week ago globenewswire.com
Cytokinetics to Announce Third Quarter Results on November 4, 2026
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 4, 2026 at…
1 week ago globenewswire.com
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on October 15, 2026 it granted stock options to purchase an aggregate of…
1 week ago zacks.com
Can Myqorzo's Expansion and Growing Adoption Drive CYTK's Growth?
Cytokinetics' Myqorzo gains commercial traction with growing prescriptions, international launches and promising clinical data that could expand its market opportunity.
-
1 week ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $140 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Cytokinetics (NASDAQ:CYTK) with a Buy and maintains $140 price target.
-
1 week ago benzinga.com
Cytokinetics Receives Notice Of Compliance From Health Canada Authorizing Treatment Use Of MYQORZO For Symptomatic Obstructive Hypertrophic Cardiomyopathy
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Health Canada has issued a Notice of Compliance authorizing MYQORZO® (aficamten) for the treatment of symptomatic obstructive…
1 week ago globenewswire.com
Cytokinetics Announces Health Canada Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Health Canada has issued a Notice of Compliance authorizing MYQORZO®…
2 weeks ago benzinga.com
Here's How Much $1000 Invested In Cytokinetics 15 Years Ago Would Be Worth Today
Cytokinetics (NASDAQ:CYTK) has outperformed the market over the past 15 years by 2.77% on an annualized basis producing an average annual return of 15.73%. Currently, Cytokinetics has a market…
2 weeks ago defenseworld.net
Rep. Gilbert Ray Cisneros, Jr. Acquires Shares of Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:TSM)
Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Taiwan Semiconductor Manufacturing Company Ltd. (NYSE: TSM). In a filing disclosed on October 12th, the…
2 weeks ago defenseworld.net
Head to Head Survey: Maze Therapeutics (NASDAQ:MAZE) and Cytokinetics (NASDAQ:CYTK)
Maze Therapeutics (NASDAQ: MAZE - Get Free Report) and Cytokinetics (NASDAQ: CYTK - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two…
-
2 weeks ago benzinga.com
Cytokinetics Presents Additional Data From Assessment Comparing Aficamten To Placebo On Cardiac Endpoints In Adults With Non-Obstructive HCM At HFSA Annual Scientific Meeting 2026
Additional Analyses from ACACIA-HCM Further Characterize Exercise Performance, Treatment Effect, Dose Titration and Safety of Aficamten in Non-Obstructive HCMSOUTH SAN FRANCISCO, Calif., Oct. 12,…
2 weeks ago globenewswire.com
Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026
Additional Analyses from ACACIA-HCM Further Characterize Exercise Performance, Treatment Effect, Dose Titration and Safety of Aficamten in Non-Obstructive HCM
2 weeks ago benzinga.com
Cytokinetics Q2 2026 Earnings Call: Complete Transcript
On Thursday, Cytokinetics (NASDAQ:CYTK) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For…
-
3 weeks ago benzinga.com
RBC Capital Maintains Outperform on Cytokinetics, Raises Price Target to $113
RBC Capital analyst Leonid Timashev maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and raises the price target from $112 to $113.
3 weeks ago defenseworld.net
Analyzing Zai Lab (NASDAQ:ZLAB) and Cytokinetics (NASDAQ:CYTK)
Cytokinetics (NASDAQ: CYTK - Get Free Report) and Zai Lab (NASDAQ: ZLAB - Get Free Report) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two…
1 month ago globenewswire.com
Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026
SOUTH SAN FRANCISCO, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four upcoming presentations, including two Late Breaking Clinical Research…
-
1 month ago benzinga.com
Cytokinetics Begins ASPEN-HCM Study Evaluating MYQORZO In Adult Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
MYQORZO is a once-daily, oral allosteric and reversible inhibitor of cardiac myosin motor activity. In patients with oHCM, myosin inhibition with MYQORZO reduces cardiac contractility and left…
1 month ago globenewswire.com
Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy
Multi-center Prospective Study to Track Real-World Safety, Clinical Effectiveness, and Healthcare Resource Impact of MYQORZO in Routine Clinical Practice
1 month ago benzinga.com
Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts Approach
B. Riley sees 40+ biotech catalysts ahead as rising rates pressure XBI, setting up a key test for the sector during the Q3 2026 earnings season.
1 month ago marketbeat.com
Cytokinetics Maps MYQORZO Expansion, Heart Failure Pipeline at Bernstein Conference
Cytokinetics NASDAQ: CYTK executives outlined the company's commercial expansion plans, cardiovascular pipeline and business-development priorities during a Bernstein investor symposium, highlighting…
1 month ago fool.com
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Both face patent cliffs and pay generous dividends, but only one of them can tell you where its next wave of growth is coming from.
1 month ago defenseworld.net
Cytokinetics (NASDAQ:CYTK) EVP Fady Ibraham Malik Sells 3,500 Shares of Stock
Cytokinetics, Incorporated (NASDAQ: CYTK - Get Free Report) EVP Fady Malik sold 3,500 shares of the firm's stock in a transaction on Tuesday, September 22nd. The shares were sold at an average price…
1 month ago benzinga.com
Here’s How Much You Would Have Made Owning Cytokinetics Stock In The Last 15 Years
Cytokinetics (NASDAQ:CYTK) has outperformed the market over the past 15 years by 2.64% on an annualized basis producing an average annual return of 15.99%. Currently, Cytokinetics has a market…
1 month ago globenewswire.com
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on September 15, 2026 it granted stock options to purchase an aggregate…
1 month ago defenseworld.net
Robert Blum Sells 97,926 Shares of Cytokinetics (NASDAQ:CYTK) Stock
Cytokinetics, Incorporated (NASDAQ: CYTK - Get Free Report) CEO Robert Blum sold 97,926 shares of Cytokinetics stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at…
1 month ago seekingalpha.com
Cytokinetics, Incorporated (CYTK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Cytokinetics, Incorporated (CYTK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
1 month ago seekingalpha.com
Cytokinetics: Why Myqorzo Doesn't Make Me A Buyer Yet
Cytokinetics, Incorporated's stock remains under pressure. At the same time, Myqorzo sales rose 427.1% quarter-over-quarter to $25.3 million in the second quarter, despite competitive pressure from…
1 month ago benzinga.com
If You Invested $1000 In Cytokinetics Stock 10 Years Ago, You Would Have This Much Today
Cytokinetics (NASDAQ:CYTK) has outperformed the market over the past 10 years by 10.3% on an annualized basis producing an average annual return of 23.89%. Currently, Cytokinetics has a market…
2 months ago benzinga.com
Cytokinetics Investors Weigh Safety Data From Pivotal Trial
Cytokinetics reports Phase 3 results for aficamten in treating hypertrophic cardiomyopathy, targeting a Q4 FDA submission.
-
2 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $140 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Cytokinetics (NASDAQ:CYTK) with a Buy and maintains $140 price target.
-
2 months ago benzinga.com
Reported Earlier, Cytokinetics Says New Trial Data Strengthens Case For Aficamten Across Heart Condition Types
Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that additional results from ACACIA-HCM (Assessment Comparing Aficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive HCM)…
-
2 months ago benzinga.com
If You Invested $100 In Cytokinetics Stock 10 Years Ago, You Would Have This Much Today
Cytokinetics (NASDAQ:CYTK) has outperformed the market over the past 10 years by 7.78% on an annualized basis producing an average annual return of 21.28%. Currently, Cytokinetics has a market…
-
2 months ago benzinga.com
Barclays Maintains Overweight on Cytokinetics, Raises Price Target to $110
Barclays analyst Emily Field maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the price target from $95 to $110.
-
2 months ago benzinga.com
JP Morgan Maintains Overweight on Cytokinetics, Raises Price Target to $103
JP Morgan analyst Tessa Romero maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the price target from $97 to $103.
-
2 months ago benzinga.com
Cytokinetics Files Delaware U.S. District Court Claim Against Bristol-Myers Squibb And MyoKardia Seeking Judgment That CYTK Isn't Infringing U.S. Patent No. 12,616,697 And That The ’697 Patent Claims Are Invalid
In the complaint, the Company requests, among other things: a judgment declaring that the Company does not infringe and has not infringed any valid claim of the ’697 patent; a judgment declaring that…
-
2 months ago benzinga.com
Truist Securities Maintains Buy on Cytokinetics, Raises Price Target to $112
Truist Securities analyst Srikripa Devarakonda maintains Cytokinetics (NASDAQ:CYTK) with a Buy and raises the price target from $106 to $112.
-
2 months ago benzinga.com
RBC Capital Maintains Outperform on Cytokinetics, Lowers Price Target to $112
RBC Capital analyst Leonid Timashev maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and lowers the price target from $117 to $112.
-
2 months ago benzinga.com
Citizens Maintains Market Outperform on Cytokinetics, Raises Price Target to $110
Citizens analyst Jason N. Butler maintains Cytokinetics (NASDAQ:CYTK) with a Market Outperform and raises the price target from $105 to $110.
-
2 months ago benzinga.com
Needham Maintains Buy on Cytokinetics, Raises Price Target to $112
Needham analyst Serge Belanger maintains Cytokinetics (NASDAQ:CYTK) with a Buy and raises the price target from $102 to $112.
-
2 months ago benzinga.com
Cytokinetics Q2 EPS $(1.50) Beats $(1.63) Estimate, Sales $28.624M Beat $17.382M Estimate
Cytokinetics (NASDAQ:CYTK) reported quarterly losses of $(1.50) per share which beat the analyst consensus estimate of $(1.63) by 7.98 percent. This is a 33.93 percent decrease over losses of $(1.12)…
-
2 months ago benzinga.com
Here's How Much $100 Invested In Cytokinetics 10 Years Ago Would Be Worth Today
Cytokinetics (NASDAQ:CYTK) has outperformed the market over the past 10 years by 7.02% on an annualized basis producing an average annual return of 20.46%. Currently, Cytokinetics has a market…
-
3 months ago benzinga.com
Cytokinetics Receives UK Marketing Authorization For MYQORZO For Treatment Of Symptomatic Obstructive Hypertrophic Cardiomyopathy In Adult Patients
At the same time the National Institute for Health and Care Excellence (NICE) has issued guidance recommending aficamten for use in eligible adult patients in England and Wales.The guidance from NICE…
3 months ago benzinga.com
New AI ETF Bets on Healthcare's $9 Trillion Opportunity
Tema's new Healthcare AI ETF (HLTH), targets AI-powered drug discovery, diagnostics, robotics and patient care.
-
3 months ago benzinga.com
RBC Capital Maintains Outperform on Cytokinetics, Lowers Price Target to $117
RBC Capital analyst Leonid Timashev maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and lowers the price target from $119 to $117.
-
3 months ago benzinga.com
Cytokinetics To Present Late Breaking Science At ESC Congress, Including Phase 3 ACACIA‑HCM Results
Hot Line Presentation of Primary Results from ACACIA-HCM to Elaborate on Positive Topline Results in Patients with Non-Obstructive Hypertrophic CardiomyopathyCompany to Host In-Person and Virtual…
3 months ago benzinga.com
8 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
-
4 months ago benzinga.com
UBS Upgrades Cytokinetics to Buy, Raises Price Target to $115
UBS analyst Ashwani Verma upgrades Cytokinetics (NASDAQ:CYTK) from Neutral to Buy and raises the price target from $69 to $115.
-
4 months ago benzinga.com
Mizuho Maintains Outperform on Cytokinetics, Raises Price Target to $118
Mizuho analyst Salim Syed maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and raises the price target from $100 to $118.